Alpha-1-Antichymotrypsin Antibody / AACT / SERPINA3

Immunohistochemistry (FFPE): 0.5-1ug/ml for 30 min at RT

The stated application concentrations are suggested starting amounts. Titration of the Alpha-1-Antichymotrypsin antibody may be required due to differences in protocols and secondary/substrate sensitivity.

Alpha 1-antichymotrypsin, or AACT, is a plasma protease inhibitor synthesized in the liver as a single glycopeptide chain. In human, the normal serum level of AACT is about one-tenth that of alpha 1-antitrypsin (AAT), with which it shares nucleic acid and protein sequence homology. Both are major acute phase reactants; their concentrations in plasma increase in response to trauma, surgery and infection. Elevated levels of AACT are widely, but not universally, reported in the cerebrospinal fluid and plasma of AD patients. Prostate-specific antigen (PSA) and its SDS-stable complex with AACT are in widespread use as markers for the diagnosis of prostate cancer. AACT deficiency may also be a possible cause of chronic liver disease. AACT antibody reacts with histiocytes and histiocytic neoplasms. It is widely used to identify histiocytes and tumors derived from them. Acinar tumors of the pancreas and salivary gland may also exhibit AACT positivity.

Purified

1 mg/ml in 1X PBS; BSA free, sodium azide free

A human partial recombinant protein was used as the immunogen for this Alpha-1-Antichymotrypsin antibody.

This Alpha-1-Antichymotrypsin antibody is available for research use only.

Cytoplasmic

Protein G affinity

P01011